Drugs / lipro insulin
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT03226210 | Feb 2015 → May 2016 | type 2 diabetes mellitus | Nanjing First Hospital, Nanjing Medical University | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | lipro insulin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03226210 ↗ |
| Known as | Prandilin | “Prandilin group (group Lis, Gan \& Lee pharmaceuticals, Beijing, China)” NCT03226210 ↗ |
| Modality | Protein / enzyme biologic | “rapid-acting insulin analogues” NCT03226210 ↗ |
| Route | Subcutaneous | “continuous subcutaneous insulin infusion (CSII)” NCT03226210 ↗ |